1 / 40

Healthcare Sector Recommendation

Healthcare Sector Recommendation. Alexander Bishop Justin Gibbs Bethaditya Winarno Jie Zhang. Agenda. Healthcare Sector Recap Recommendation Q&A. Health Care Recap. SIM Holdings. Recommendation. Buy 72 bp of Gilead Buy 100 bp of Teva Sell 84 bp of Care Fusion Reduce 50 bp of Amgen.

kendall
Télécharger la présentation

Healthcare Sector Recommendation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Healthcare Sector Recommendation Alexander Bishop Justin Gibbs Bethaditya Winarno Jie Zhang

  2. Agenda • Healthcare Sector Recap • Recommendation • Q&A

  3. Health Care Recap

  4. SIM Holdings

  5. Recommendation • Buy 72 bp of Gilead • Buy 100 bp of Teva • Sell 84 bp of Care Fusion • Reduce 50 bp of Amgen

  6. Gilead Sciences • Founded in 1987 • Biopharmaceutical company that discovers, develops and commercializes therapeutics • Specializes in HIV/AIDS therapies and Hepatitis B therapies • Derives the majority of revenues through product sales

  7. Gilead Advantages • HIV Franchise • Atripla and Truvada account for nearly 70% of patients on HIV therapy • Patients on antiretroviral therapy has grown by 4% on an annual moving total basis • Truvada and Atripla sales have increased 30% • Gilead captures 85% treatment naïve patients • Hepatitis B Franchine • CV Therapeutics • Cayston approval

  8. Gilead- Advantages • Government Action • Veterans Administration • Medicare • California • Ryan White Healthcare Act • US Dept. of Health and Human Services • Non-retail sales

  9. Gilead- Advantages • Patent Expiration

  10. Gilead- Advantages • Pipeline

  11. Gilead- Risks • Truvada and Atripla account for 70% total revenues • Royalty revenue and Tamiflu • Pipeline • FX Exchange • Healthcare reform and reimbursements • Competition

  12. Gilead- Revenue Growth • 31% between 08 and 09, topped $7 billion

  13. Gilead- Valuation Analysis

  14. Gilead- Valuation Analysis Current Price: $47.10 Target Price: $69.11 Implied Upside: 46% DCF Target Price: $68.36 DCF Upside: 45% Weighted Average Upside: $68.74, 45.5%

  15. Gilead- DCF

  16. Gilead- Sensitivity Matrix

  17. Gilead- Performance YTD

  18. Gilead- Performance 1yr

  19. Gilead- Performance 3yr

  20. Gilead- Performance 10yr

  21. Lines of business • API- Active Pharmaceutical Ingredients. • Vertical integration • Higher operating margins • Core competency

  22. Generic drugs • 75% of sales • Must be bioequivalent of their predecessors. • Can’t be marketed until patents are expired or proven illegitimate.

  23. Branded drugs • Increased investment, expected output to be doubled between 2007 and 2012 • Risky

  24. Macro drivers in Teva’s favor • Aging of the population

  25. Increasing health concerns

  26. Increased government spending leads to cost cutting efforts=generic drugs have an advantage

  27. Company Overview (CFN) • Global medical technology company providing healthcare products and services • Offer products in areas of intravenous, infusion, medication and supply dispensing, respiratory care, infection prevision, and surgical instruments. • 2 main lines of business: • Critical Care Technologies • Medical Technologies and Services

  28. CFN Status Quo • Market Cap: 5.75 B • SIM Weight: 0.84% • Current Price: $29.7 • Target Price: $27.8 • Upside:6.81%

  29. Market Performance (6 months)

  30. Valuation Target Price = $ 28.16

  31. Leverage: • Demographic factors • Technology leadership and innovation • Favorable valuation Risks: • Inability to enhance existing products or introduce new products • Subject to complex and costly regulation • 2nd Quarter earnings drop & below expectation • Uncertainty after the spinoff from Cardinal Health • Significant amount of indebtedness

  32. Decrease Amgen Inc. (AMGN) by 50 bps Current Weight: 250 bps • Prolia (Osteoporosis drug) likely to be approved by FDA • Decrease weight to avoid loss due to failure to secure Prolia, maintain significant weight to maintain exposure to future revenue growth • No near future patent expiration • Favorable tax incentives due to increased profits and operations in international locations (Puerto Rico) tax rate dropped to 11.5% from 20% • Advancing pipeline, long term potential growth, wide variety of drugs in various phases in the pipeline

  33. Questions?

More Related